BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Job Trends

  Argus Worldwide Corp. unveils plans to overhaul digital/internet technology unit; Company to launch CyberJ Inc.

  Argus Worldwide Corp. reported that the Company will restructure its digital/internet unit under a new global technology business initially comprised of its Cyber Junky unit and the 40% interest in India based Tejovat Technologies Pvt Ltd., which the Company is currently acquiring.

  June 13, 2018

   · 

  2 min read
• Quebecers Living with Advanced Parkinson’s Disease Now Have Broader Access to NEUPRO (rotigotine) As Add-On Therapy

  UCB Canada Inc. announced today that Quebecers now have publicly funded access (special authorization) to NEUPRO® (rotigotine) for the treatment of advanced stage Parkinson’s Disease (APD), in combination with the drug levodopa.

  June 13, 2018

   · 

  4 min read
• Business

  BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference

  BioLineRx Ltd. announced today that its Chief Executive Officer, Philip Serlin, will participate in a panel discussion at JMP Securities 2018 Life Sciences Conference

  June 13, 2018

   · 

  2 min read
• BioMidwest

  Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities 2018 Life Sciences Conference

  Deciphera Pharmaceuticals, Inc. today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the JMP Securities 2018 Life Sciences Conference.

  June 13, 2018

   · 

  1 min read
• Business

  BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders

  BridgeBio Pharma announced the launch of CoA Therapeutics, a biopharmaceutical company developing novel small-molecules designed to increase Coenzyme-A (CoA) levels in genetic disorders where CoA deficiency is implicated.

  June 13, 2018

   · 

  3 min read
• Business

  Cardax Engages Industry Veteran Fred Sancilio, Ph.D., to Launch Orphan Drug Development Program

  Inflammation’s major role in chronic orphan diseases supports program’s strong potential

  June 13, 2018

   · 

  4 min read
• Genetown

  Analgesic Solutions Presents Data from the Implementation of its Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS®)

  Company Establishes Scientific Advisory Board for the MADDERS

  June 13, 2018

   · 

  5 min read
• Biotech Bay

  Shifamed Announces $15.5M Series A Financing

  Supira Medical, Newly Formed Portfolio Company, Focuses On Next Generation pVAD

  June 13, 2018

   · 

  1 min read
• Drug Development

  Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer

  Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial.

  June 13, 2018

   · 

  8 min read
• Business

  Cardinal Health and Clayton, Dubilier & Rice Announce Partnership to Accelerate Growth of naviHealth

  Investment Accelerates naviHealth’s Growing Market Position in Post-Acute Care Management

  June 13, 2018

   · 

  5 min read